(RTTNews) - AVITA Medical, Inc. (RCEL), a regenerative medicine company focused on innovative wound care solutions, announced that the U.S. Food and Drug Administration has approved its premarket approval supplement for the RECELL GO mini.
RECELL GO mini is a new, smaller version of the RECELL GO system, designed specifically to treat wounds up to 480 square centimeters, compared to the standard RECELL GO cartridge, which covers 1,920 square centimeters.
This approval addresses a critical need for smaller wound treatments, particularly in trauma and burn centers.
"We are excited to offer a tailored solution for clinicians treating smaller wounds," said Jim Corbett, CEO of AVITA Medical. "This approval will drive greater adoption of the RECELL technology across trauma centers and provide expanded access to a broader patient population."
The company expects to roll out the RECELL GO mini to trauma and burn centers starting in the first quarter of 2025. This addition to the RECELL platform is expected to be a key growth driver for AVITA Medical.
RCEL closed Monday's (Dec. 23, 2024) trading at $11.75, down 0.17%. In premarket trading, the stock is up 8.94% to $12.80.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
